Overview

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

Status:
Recruiting
Trial end date:
2025-02-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborator:
Iltoo Pharma
Treatments:
Interleukin-2